Krystal Biotech, Inc. (KRYS) research: valuation against peers, fundamentals over time, risk and news coverage
KRYS
Krystal Biotech, Inc.No data in this window.
Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.
- SPECIAL REPORTBEARISHExecutives Across Biotech, Software and Media Sold Over $80 Million in Stock in a Single Stretch
Illumina director Keith Meister sold $57.2 million in stock, the largest of at least seven insider sales disclosed in the period, together totaling well over $80 million across unrelated sectors.
- SPECIAL REPORTBEARISHInsider Selling Wave Sweeps High-Multiple Growth and Biotech Names
A dense cluster of Form 4 filings shows heavy insider distribution across software and biotechnology, led by a $16.8 million Snowflake director sale and roughly $15.5 million of combined Rhythm Pharmaceuticals executive sales, while insider buying was limited to a single Dutch Bros board purchase.
Every figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.